DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and international markets, beating consensus expectations and pairing this with guidance ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...